KRAS: A Druggable Target in Colon Cancer Patients
Related Experiment Video
Updated: Sep 26, 2025
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Francesca Negri1, Lorena Bottarelli2, Gian Luigi de'Angelis1,2
1Gastroenterology and Endoscopy Unit, Azienda Ospedaliero-Universitaria di Parma, 43126 Parma, Italy.
Abstract:
Mutations in KRAS are among the most frequent aberrations in cancer, including colon cancer. KRAS direct targeting is daunting due to KRAS protein resistance to small molecule inhibition. Moreover, its elevated affinity to cellular guanosine triphosphate (GTP) has made the design of specific drugs challenging. Indeed, KRAS was considered 'undruggable'. KRASG12C is the most commonly mutated variant of KRAS in non-small cell lung cancer. Currently, the achievements obtained with covalent inhibitors of this variant have given the possibility to assess the best therapeutic approach to KRAS-driven tumors. Mutation-related biochemical assets and the tissue of origin are expected to influence responses to treatment. Further attempts to obtain mutant-specific KRAS (KRASG12C) switch-II covalent inhibitors are ongoing and the results are promising. Drugs targeted to block KRAS effector pathways could be combined with direct KRAS inhibitors, immunotherapy or T cell-targeting approaches in KRAS-mutant tumors. The development of valuable combination regimens will be essential against potential mechanisms of resistance that may arise during treatment.
Insights
Targeting KRAS mutations, once considered undruggable, is now possible with covalent inhibitors, especially for KRASG12C. Combination therapies show promise for treating KRAS-driven cancers.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- KRAS mutations are frequent in cancers like colon and lung cancer.
- KRAS proteins are challenging to target directly due to their biochemical properties, leading to the 'undruggable' classification.
- The KRASG12C variant is prevalent in non-small cell lung cancer.
Purpose of the Study:
- To review the therapeutic strategies for KRAS-mutant tumors.
- To discuss the advancements in targeting KRAS, particularly the KRASG12C variant.
- To explore potential combination therapies for KRAS-driven cancers.
Main Methods:
- Review of current literature on KRAS inhibitors and targeted therapies.
- Analysis of the challenges and successes in developing KRAS-specific drugs.
- Evaluation of emerging combination treatment strategies.
Main Results:
- Covalent inhibitors have shown success against the KRASG12C variant.
- Treatment response is influenced by mutation-specific biochemical profiles and tumor origin.
- Ongoing research for mutant-specific KRAS inhibitors is yielding promising results.
Conclusions:
- Direct targeting of KRAS, especially KRASG12C, is becoming a viable therapeutic strategy.
- Combination regimens involving direct KRAS inhibitors, immunotherapy, or T cell-targeting approaches are crucial.
- Developing effective combination therapies is essential to overcome resistance mechanisms in KRAS-mutant tumors.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...